CT Imaging for Guiding PA-TACE for HCC
CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma
1 other identifier
observational
1,770
1 country
1
Brief Summary
Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2019
CompletedFirst Submitted
Initial submission to the registry
November 23, 2023
CompletedFirst Posted
Study publicly available on registry
December 5, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedJuly 28, 2025
November 1, 2023
5.8 years
November 23, 2023
July 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall survival
Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.
the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.
Study Arms (2)
Hepatectomy alone
PA-TACE
Interventions
HCC patients received hepatectomy and PA-TACE.
Eligibility Criteria
This study included 1,488 patients (median age, 52 years \[IQR, 45-61 years\]; 1,309 male).
You may qualify if:
- CT scans acquired no more than one month before surgery
- Confirmation of HCC diagnosis by pathological examination
- Curative surgical resection
You may not qualify if:
- Prior antitumor treatment
- Macrovascular thrombosis or metastasis
- Perioperative mortality
- Unqualified image artifacts
- Tumor rupture
- MVI status not reported
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
ZhuJiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510280, China
Related Publications (1)
Li X, Liang X, Li Z, Liang J, Qi Z, Zhong L, Geng Z, Liang W, Quan X, Liang C, Liu Z. A novel stratification scheme combined with internal arteries in CT imaging for guiding postoperative adjuvant transarterial chemoembolization in hepatocellular carcinoma: a retrospective cohort study. Int J Surg. 2024 May 1;110(5):2556-2567. doi: 10.1097/JS9.0000000000001191.
PMID: 38377071DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Academic Head of Department of Radiology
Study Record Dates
First Submitted
November 23, 2023
First Posted
December 5, 2023
Study Start
October 1, 2019
Primary Completion
June 30, 2025
Study Completion
June 30, 2025
Last Updated
July 28, 2025
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will not share